NV-387: A Promising Antiviral Agent for Measles

In a recent interview with Steve Darling from Proactive, NanoViricides CEO Dr. Anil Diwan discussed the company's progress in developing NV-387, an antiviral drug showing significant promise against measles. This drug has demonstrated potent activity in cell culture and humanized animal models, offering a potential lifeline amid rising measles outbreaks globally.

NV-387 not only extends survival in lethal measles models but also protects lung tissue, a critical achievement as severe infections can lead to death. As there are currently no approved treatments for measles, these findings present a significant breakthrough.

The company revealed that NV-387 has successfully passed Phase I human trials without adverse effects, positioning it for emergency use applications under FDA guidelines. Additionally, its formulation as oral gummies offers a practical advantage for patients, particularly those with rashes or throat irritation.

Looking ahead, NV-387 is set to enter Phase II clinical trials for MPox treatment, highlighting its broad-spectrum potential against various viral infections.